MiNK Therapeutics (INKT) Total Liabilities (2020 - 2026)
MiNK Therapeutics (INKT) posted Total Liabilities of $10.4 million for Q1 2026, down 27.12% sequentially from $14.2 million in Q4 2025, and up 143.17% YoY from $4.3 million in Q1 2025.
MiNK Therapeutics (INKT) Total Liabilities (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $10.4 million in Q1 2026.
- Quarterly Total Liabilities rose 143.17% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.4 million (up 143.17% YoY) and the FY2025 annual result came in at $14.2 million, up 148.9% from the prior year.
- Total Liabilities retreated to $10.4 million in Q1 2026 per INKT's latest filing, from $14.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $36.1 million in Q1 2022 and troughed at $2.5 million in Q2 2025.
- A 5-year average of $13.6 million and a median of $10.4 million in 2026 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 519.56% in 2022, then tumbled 78.8% in 2023.
- Over 5 years, Total Liabilities stood at $21.5 million in 2022, then sank by 78.8% to $4.6 million in 2023, then gained by 25.67% to $5.7 million in 2024, then surged by 148.9% to $14.2 million in 2025, then slipped by 27.12% to $10.4 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $10.4 million, $14.2 million, and $15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | MiNK Therapeutics | 60.53 Mn | 60.53 Mn | - | 9.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.62 Mn |
| Mar 31, 2026 | 10.38 Mn |
| Dec 31, 2025 | 14.24 Mn |
| Sep 30, 2025 | 14.96 Mn |
| Jun 30, 2025 | 2.48 Mn |
| Mar 31, 2025 | 4.27 Mn |
| Dec 31, 2024 | 5.72 Mn |
| Sep 30, 2024 | 7.37 Mn |
| Jun 30, 2024 | 10.32 Mn |
| Mar 31, 2024 | 6.89 Mn |
| Dec 31, 2023 | 4.55 Mn |
| Sep 30, 2023 | 7.46 Mn |
| Jun 30, 2023 | 12.11 Mn |
| Mar 31, 2023 | 16.59 Mn |
| Dec 31, 2022 | 21.47 Mn |
| Sep 30, 2022 | 25.26 Mn |
| Jun 30, 2022 | 31.12 Mn |
| Mar 31, 2022 | 36.14 Mn |
| Dec 31, 2021 | 40.24 Mn |
| Sep 30, 2021 | 4.08 Mn |